"What's needed is robust, real action to lower the price for everyone, not just a select few." He says the EpiPen has such enormous market share that the company may be violating antitrust laws by exploiting that. A report by the health care website Stat says some of Mylan's contracts to give schools free or discounted EpiPens may have done just that, because they bar the schools from buying competitors' products. Mylan told Stat that the provision restricting school purchasing has since been discontinued, but did not say when it was halted. Blumenthal is just one of several lawmakers who have called for investigations into Mylan's business practices and have asked for justifications of its price increases in recent days. He and a few others say the discounts aren't enough. Blumenthal sent a letter to the company earlier this week demanding that it lower the price. Sen. Charles Grassley, R-Iowa, sent a letter to Mylan demanding an explanation for the increase.